These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27253622)

  • 1. Subcutaneously Administered Self-Cleaving Hydrogel-Octreotide Conjugates Provide Very Long-Acting Octreotide.
    Schneider EL; Henise J; Reid R; Ashley GW; Santi DV
    Bioconjug Chem; 2016 Jul; 27(7):1638-44. PubMed ID: 27253622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide.
    Schneider EL; Henise J; Reid R; Ashley GW; Santi DV
    Bioconjug Chem; 2016 May; 27(5):1210-5. PubMed ID: 26930186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system.
    Hearn BR; Fontaine SD; Pfaff SJ; Schneider EL; Henise J; Ashley GW; Santi DV
    J Control Release; 2018 May; 278():74-79. PubMed ID: 29577950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist.
    Schneider EL; Hearn BR; Pfaff SJ; Reid R; Parkes DG; Vrang N; Ashley GW; Santi DV
    ACS Chem Biol; 2017 Aug; 12(8):2107-2116. PubMed ID: 28605180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A long-acting C-natriuretic peptide for achondroplasia.
    Schneider EL; Carreras CW; Reid R; Ashley GW; Santi DV
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2201067119. PubMed ID: 35858423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydrogel drug delivery system with predictable and tunable drug release and degradation rates.
    Ashley GW; Henise J; Reid R; Santi DV
    Proc Natl Acad Sci U S A; 2013 Feb; 110(6):2318-23. PubMed ID: 23345437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.
    Schneider EL; Reid R; Parkes DG; Lutz TA; Ashley GW; Santi DV
    Domest Anim Endocrinol; 2020 Jan; 70():106373. PubMed ID: 31479925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sandostatin LAR in acromegalic patients: a dose-range study.
    Fløgstad AK; Halse J; Haldorsen T; Lancranjan I; Marbach P; Bruns C; Jervell J
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3601-7. PubMed ID: 8530606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
    de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ
    Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
    Su Z; Niu J; Xiao Y; Ping Q; Sun M; Huang A; You W; Sang X; Yuan D
    Mol Pharm; 2011 Oct; 8(5):1641-51. PubMed ID: 21770405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.
    Gillis JC; Noble S; Goa KL
    Drugs; 1997 Apr; 53(4):681-99. PubMed ID: 9098666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K; Cheer S; Wagstaff AJ
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
    Penning C; Vecht J; Masclee AA
    Aliment Pharmacol Ther; 2005 Nov; 22(10):963-9. PubMed ID: 16268971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide.
    Wang M; Shan F; Zou Y; Sun X; Zhang ZR; Fu Y; Gong T
    J Control Release; 2016 May; 230():45-56. PubMed ID: 27040814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
    Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
    Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of congenital hyperinsulinism with long-acting release octreotide.
    Le Quan Sang KH; Arnoux JB; Mamoune A; Saint-Martin C; Bellanné-Chantelot C; Valayannopoulos V; Brassier A; Kayirangwa H; Barbier V; Broissand C; Fabreguettes JR; Charron B; Thalabard JC; de Lonlay P
    Eur J Endocrinol; 2012 Feb; 166(2):333-9. PubMed ID: 22048969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
    Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
    J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of Octreotide LAR vs. octreotide tid for pain and quality of life in chronic pancreatitis.
    Lieb JG; Shuster JJ; Theriaque D; Curington C; Cintrón M; Toskes PP
    JOP; 2009 Sep; 10(5):518-22. PubMed ID: 19734628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo evaluation of an in situ gel forming system for the delivery of PEGylated octreotide.
    Erfani Jabarian L; Rouini MR; Atyabi F; Foroumadi A; Nassiri SM; Dinarvand R
    Eur J Pharm Sci; 2013 Jan; 48(1-2):87-96. PubMed ID: 23131800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.